Breaking News, Collaborations & Alliances

Vir Biotechnology Completes Astellas Deal to Advance Prostate Cancer Immunotherapy

Astellas and Vir Biotechnology to co-develop and co-commercialize VIR-5500 through a sharing of expenses and revenues.

Author Image

By: Charlie Sternberg

Associate Editor

Vir Biotechnology has entered a global strategic collaboration with Astellas Pharma to co-develop and commercialize an experimental immunotherapy for prostate cancer, following regulatory clearance under U.S. antitrust law. The agreement centers on VIR‑5500, a prostate-specific membrane antigen (PSMA)–targeted T‑cell engager designed to treat advanced prostate cancer. The companies announced the partnership in February and said Thursday that the deal closed after the expiration of the waiting...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters